期刊文献+

匹多莫德抑制频发性生殖器疱疹复发的临床观察 被引量:7

Comparative study of intermitant and suppressive pidotimod therapy for recurrent genital herpes
暂未订购
导出
摘要 目的观察在阿昔洛韦治疗基础上,匹多莫德间歇冲击疗法和长程抑制疗法对复发性生殖器疱疹复发频率及复发次数的抑制效果。方法 52例复发性生殖器疱疹患者按照半随机方式分配至间歇冲击治疗组(A组)和长程抑制治疗组(B组),两组均在生殖器疱疹复发就诊时开始给予常规阿昔洛韦基础治疗。A组27例,仅在疱疹复发时口服匹多莫德0.8 g,2次/d,连服10 d;B组25例,口服匹多莫德0.4 g,1次/d,连服6个月,治疗后观察随访12个月。结果在6个月治疗期间,A、B两组的复发率和平均复发次数无显著性差异,而在治疗后的12个月随访期间,B组的复发率及平均复发次数均明显低于A组。结论在阿昔洛韦治疗基础上,匹多莫德长程抑制疗法可有效降低复发性生殖器疱疹的复发率,减少复发次数,其疗效明显优于间歇冲击疗法。 Objective To compare the preventing efficacy of intermitant and suppressive pidotimod therapy for genital herpes recurence.Methods 52 patients with recurrent genital herpes were firstly stratified according to their different frequency of recurence,and then hemi-randomly divided into two groups: the intermitant treatment group(group A) and the suppressive therapy group(group B).For all cases acylovir were given 0.4mg,twice daily consecutively for 6 months as basic therpy.For the 27 cases of group A,pidotimod was given 0.8,twice daily for 10 days only when the herpes relapsed.For the 25 cases of group B,pidotimod was given 0.4 once daily consecutively for 6 months.Both groups were followed-up for 12 months after the 6-month treatment.Results The average recurrent times per six months and the recurent rate of group A and group B were not significantly different during the 6-month therapy period.But the average recurrent times per six months and the recurent rate of group B was significantly lower than that of group A during the thereafter 12-month follow-up period.Conclusion The suppressive therapy of pidotimod has good effect for preventing genital herpes recurrence,and is significantly better than the intermitant treatment.
作者 林大东
机构地区 解放军第
出处 《临床军医杂志》 CAS 2010年第6期1007-1009,共3页 Clinical Journal of Medical Officers
  • 相关文献

参考文献1

二级参考文献25

  • 1Al-Khatib K,Campbell IL,Carr DJ.Resistance to ocular herpes simplex virus type 1 infection in IL-12 transgenic mice.J Neuroimmunol,2002,132:41-48.
  • 2Paul WE.Fundamental Inmunology.4th edit.USA:Lippincott Williams & Wilkins,1999.884-900.
  • 3Paul WE.Fundamental Immunology.4th edit.USA:Lippincott Williams & Wilkins,1999.765-767.
  • 4Wang JH,Layden TJ,Eckels DD.Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus:transition from a Th1 to a Th2 response.Hum Immunol,2003,64:662-673.
  • 5Bertoletti A,D'Elios MM,Boni C,et al.Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.Gastroenterology,1997,112:193-199.
  • 6Scott M,Stites DP,Moscicki AB.Th1 cytokine patterns in cervical human papillomavirus infection.Clin Diagn Lab Immunol,1999,6:751-755.
  • 7El-Sherif AM,Seth R,Tighe PJ,et al.Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer.J Pathol,2001,195:179-185.
  • 8Ramalingam S,Kannangai R,Vijayakumar TS,et al.Subtype & cytokine profiles of HIV infected individuals from south India.Indian J Med Res,2005,121:226-234.
  • 9Mezentseva MV,Narovlyansky AN,Scherbenko VE,et al.Analysis of the interferon status and cytokine profile in patients with genital herpes.Russ J Immunol,2002,7:167-174.
  • 10Singh R,Kumar A,Creery WD,et al.Dysregulated expression of IFN-gamma and IL-10 and impaired IFN-gamma-mediated responses at different disease stages in patients with genital herpes simplex virus-2 infection.Clin Exp Immunol,2003,133:97-107.

共引文献11

同被引文献74

引证文献7

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部